Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Intrahepatic cholangiocarcinoma (iCCA) is a malignant tumor originating within the intrahepatic bile ducts and is a form of bile duct cancer. According to Yaqoob Muhammad et al. (2026), iCCA ranks as the second most common primary liver cancer, accounting for approximately 20% of cases. According to Expert Market Research, cholangiocarcinoma incidence globally is rising, driven by increasing disease burden, improved diagnostic capabilities, and greater recognition of associated risk factors.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Intrahepatic Cholangiocarcinoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of intrahepatic cholangiocarcinoma. It projects the future incidence and prevalence rates of intrahepatic cholangiocarcinoma cases across various populations. The study covers age, gender, and type as major determinants of the intrahepatic cholangiocarcinoma population. The report highlights patterns in the prevalence of intrahepatic cholangiocarcinoma over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of intrahepatic cholangiocarcinoma in the 8 major markets.
Regions Covered
Intrahepatic cholangiocarcinoma (iCCA) is a malignant tumor arising from the epithelial cells of the intrahepatic bile ducts within the liver. It develops when genetic and molecular alterations disrupt normal biliary cell growth, resulting in uncontrolled proliferation and tumor formation. iCCA is anatomically distinct from extrahepatic cholangiocarcinoma and is generally classified according to its histologic and molecular characteristics. Histologically, the major patterns include small-duct and large-duct types, which differ in their associated risk factors and molecular profiles. Bile duct cancer can remain asymptomatic during early stages, contributing to diagnosis at advanced disease stages.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Country |
India |
|
High-Risk Population |
Older adults and individuals with chronic biliary tract disease |
|
Key Diagnostic Method |
Contrast-enhanced magnetic resonance imaging and computed tomography, supported by tissue diagnosis |
|
Major Risk Factor |
Primary sclerosing cholangitis, hepatolithiasis, and chronic biliary inflammation |
|
Major gap in the market |
Late diagnosis and limited availability of effective curative treatment for advanced disease |
The intrahepatic cholangiocarcinoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the intrahepatic cholangiocarcinoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for intrahepatic cholangiocarcinoma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
Intrahepatic cholangiocarcinoma represents approximately 10%–15% of primary hepatic malignancies and is the second most common primary liver cancer. According to Yaqoob Muhammad et al. (2026), it accounts for about 20% of primary liver cancer cases, with global incidence increasing over the past four decades. |
|
Gender-Specific Cases of the Disease |
Gender differences are observed in cholangiocarcinoma epidemiology. According to Jianguo Chen et al. (2026), the 2024 age-adjusted mortality rate was higher among men than women at 3.70 versus 3.11 per 100,000, respectively, although mortality increased faster among women. |
|
Age-Specific Cases of the Disease |
Intrahepatic cholangiocarcinoma predominantly affects older adults. According to François Ghiringhelli et al. (2023), half of biliary tract cancer patients were older than 75 years at diagnosis. Jianguo Chen et al. (2026) reported the highest crude mortality among adults aged 85 years or older. |
|
Ethnicity-Wise Cases of the Disease |
Ethnic differences have been reported in mortality patterns. As per Jianguo Chen et al. (2026), Hispanic individuals had the highest age-adjusted mortality rate at 3.47 per 100,000, while non-Hispanic Black individuals had the largest annual percentage increase at 4.03%. |
|
Mortality and Survival Analysis of the Disease |
Mortality has increased substantially over time. According to Jianguo Chen et al. (2026), annual deaths increased from 2,552 in 1999 to 9,752 in 2024, while the age-adjusted mortality rate increased from 1.44 to 3.35 per 100,000. Yaqoob Muhammad et al. (2026) reported five-year survival below 10%. |
|
Disease Type |
Prevalence |
|
Small-Duct Type Intrahepatic Cholangiocarcinoma |
Small-duct type iCCA is one of the two principal anatomical subtypes and arises from smaller intrahepatic bile ducts. Its epidemiological assessment is relevant to understanding differences in disease distribution and burden within intrahepatic cholangiocarcinoma. |
|
Large-Duct Type Intrahepatic Cholangiocarcinoma |
Large-duct type iCCA represents the second major anatomical subtype and originates from larger intrahepatic bile ducts. Epidemiological assessment of this subtype contributes to understanding the heterogeneity of intrahepatic cholangiocarcinoma and its distribution across patient populations. |

Read more about this report - Request a Free Sample
The intrahepatic cholangiocarcinoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
The United States has experienced a substantial increase in the intrahepatic cholangiocarcinoma burden. According to the National Organization for Rare Disorders, approximately 6,000 intrahepatic cholangiocarcinoma cases are diagnosed annually, with an incidence of approximately 1.49 per 100,000 people. According to Jianguo Chen et al. (2026), annual deaths increased from 2,552 in 1999 to 9,752 in 2024, accompanied by a rise in the age-adjusted mortality rate. |
|
Germany |
The epidemiological profile in Germany is influenced by the concentration of biliary tract cancer among older populations. According to François Ghiringhelli et al. (2023), half of biliary tract cancer patients were older than 75 years at diagnosis, highlighting the importance of advanced age in the observed disease burden. |
|
France |
France demonstrates a substantial intrahepatic component within the biliary tract cancer burden. |
|
Italy |
The epidemiological burden in Italy is shaped by the age distribution of biliary tract cancer. A significant share of biliary tract cancer patients are older than 75 years at diagnosis, supporting the importance of the aging population in the epidemiological profile of these malignancies. |
|
Spain |
Epidemiological patterns in Spain can be considered in the context of documented sex and age differences in biliary tract cancer. Cholangiocarcinoma mortality is higher among men globally, while an increasing burden of biliary tract cancer among younger adults has been observed across several geographic regions. |
|
United Kingdom |
Epidemiological patterns in the United Kingdom reflect the broader sex- and age-related characteristics of biliary tract malignancies. According to Jiao Su et al. (2024), cholangiocarcinoma mortality is higher among men than women globally, while the increasing burden of biliary tract cancer among younger adults has also been reported across different geographic regions. |
|
Japan |
Japan has a notable intrahepatic cholangiocarcinoma burden within Asia. According to Masashi Mizumoto et al. (2023), age-adjusted prevalence was 1.25 per 100,000 person-years among men and 0.77 per 100,000 person-years among women, indicating a higher reported burden among men. |
|
India |
India contributes to the epidemiological burden of biliary tract malignancies in Asia. According to Masashi Mizumoto et al. (2023), intrahepatic cholangiocarcinoma prevalence is high in Asia. Jiao Su et al. (2024) further reported geographic variation in biliary tract cancer burden, supporting the relevance of regional differences in epidemiological patterns. |
The regional disease epidemiology landscape for intrahepatic cholangiocarcinoma is characterized by substantial challenges in early detection, accurate diagnosis, and identification of actionable molecular alterations. Limited disease-specific symptoms often result in diagnosis at advanced stages, reducing opportunities for curative surgery. Molecular profiling represents an important emerging opportunity because identifying actionable alterations can support the selection of targeted therapies in eligible patients. Expanding access to specialized hepatobiliary imaging, pathology, and comprehensive genomic testing may improve diagnostic characterization across the United States, Europe, Japan, and India. Continued development of earlier detection strategies also represents an important unmet need.
Intrahepatic cholangiocarcinoma treatment depends on tumor stage, anatomical location, resectability, molecular characteristics, and the patient's overall health. Surgical resection with curative intent is the primary treatment for localized, resectable disease. For unresectable or advanced disease, systemic therapy is commonly used, including platinum-based chemotherapy combined with gemcitabine and, where appropriate, immunotherapy. Targeted therapies may be considered when actionable alterations, such as fibroblast growth factor receptor 2 fusions or isocitrate dehydrogenase mutations, are identified. Cholangiocarcinoma treatment may also incorporate radiation therapy, locoregional approaches, and palliative care to manage symptoms and disease progression.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.